Find Funding Opportunities

This NINDS Notice provides additional guidance for requesting funded extensions for NINDS K award recipients impacted by COVID-19.

The purpose of this notice is to inform applicants of a correction to the Eligibility Information for PAR-21-315 "Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)". For this Funding Opportunity Announcement (FOA), "Section III. Eligibility Information" and "Section IV. Application and Submission Information, 7. Other Submission Requirements and Information" have been corrected to allow intramural participation.

This NOSI supports creation of data archive(s), development of software tools, and establishment of data standards for BBQS-related studies to address the above-described challenges in the research program. The informatics infrastructure and tools to be developed under this NOSI are expected to be widely used by BBQS investigators, as well as by a broader community. Applications in response to this NOSI should therefore clearly justify the importance and implications of the proposed informatics infrastructure or tools to the BBQS program, and identify the potential user base. The projects funded under this NOSI are expected to support, communicate and collaborate with the funded BBQS research projects. Applicants should therefore familiarize themselves with the BBQS research program and funded projects (https://www.braininitiative.nih.gov/funding/initiatives.htm; also see RFA-MH-22-240 and RFA-DA-23-030).

Expiring the FOA

The Purpose of this Notice is to inform potential applicants that the National Institute of Neurological Disorders and Stroke (NINDS) is participating, effective immediately, in RFA-TR-22-030 "Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trials Not Allowed).

The purpose of this notice is to inform applicants of a change to the Eligibility Information for RFA-Ns-22-050 "HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)". The Funding Opportunity Announcement (FOA) has been modified to show that "foreign components, as defined in the NIH Grants Policy Statement, are allowed.

The purpose of this notice is to add NINDS-specific research interests in PAS-22-196 "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)".

The overarching goal of this program is to enhance the retention of investigators facing critical life events who are transitioning from mentored career development awards to research independence and to minimize departures from biomedical research workforce. This supplement program is intended to ensure continuity of research among recipients of mentored career development (K) awards by providing supplemental research support to help sustain the investigators research during a period in which the PD/PI experiences critical life events which have the potential to impact research progress or potential productivity. Administrative supplements must support work within the scope of the original project.

The purpose of this notice is to add NINDS-specific research interests in PAS-22-197 "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)".

The overarching goal of this program is to enhance the retention of investigators facing critical life events who are transitioning to the first renewal of their first independent research project grant award or to a second new NIH research project grant award. Retention at the first renewal or continuous NIH research project grant support is crucial for sustaining both the ongoing research NIH has made an investment in and for retaining diverse talent in the biomedical research workforce. This program supports at-risk investigators as identified in the NIH Next Generation Researchers Initiative (see https://grants.nih.gov/ngri.htm).